Compare Cytokinetics Inc (CYTK) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tripadvisor Inc Common Stock — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: Cytokinetics Inc is far larger — about 8.5× Tripadvisor Inc Common Stock's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| CYTK | TRIP | |
|---|---|---|
Market Cap | $8.62B | $1.01B |
Volume | 2,594,626 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $16.72 |
52-Week Low | $54.76 | $8.04 |
Typical Hold Time | 19 Days | 57 Days |
Enterprise Value | $8.72B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
TripAdvisor (TRIP) trades at $8.63, up 1.29% on the day but near its 52-week low of $8.27. The stock is technically bearish, with recent earnings misses and a net cash outflow of $29M in 2025. Revenue grew to $1.89B in 2025, but net margins remain thin at 0.27%. Analyst sentiment is mixed, with a consensus price target of $13.58 but a majority hold rating.
The outlook is cautious. Upside potential exists if the Viator segment recovers and TheFork sale concludes, but risks include persistent earnings volatility, competitive pressure from AI travel tools, and weak cash flow trends. The stock offers value on P/S (0.57) but requires improved execution to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
